The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Treatment selection for patients with multiple myeloma at first relapse and beyond
Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses the evolving treatment landscape of multiple myeloma at first relapse and beyond. Prof. Delforge discusses factors that can influence treatment decisions, such as prior treatment, patient characteristics and lenalidomide refractoriness. Following this, Prof. Delforge compares triplet regimens and their suitability for different patient groups, and discusses studies that have assessed the efficacy of pomalidomide-based regimens. CAR-T therapy also presents a promising option for these patients, with encouraging results observed in the KarMMa-3 and CARTITUDE-4 trials (NCT03651128; NCT04181827). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
